Open OfferMay 19, 2026, 04:13 PM
Sunshine Biopharma Closes $6M Public Offering
AI Summary
Sunshine Biopharma Inc. announced the closing of its public offering on May 19, 2026, raising approximately $6 million in gross proceeds. The offering consisted of Common Units and Pre-Funded Units, each including shares or pre-funded warrants and two Series C warrants. Aegis Capital Corp. acted as the exclusive placement agent, receiving a 7% fee and a 2% expense allowance. The company anticipates using the net proceeds for general corporate purposes and working capital, with a potential for an additional $12 million if all Series C warrants are fully exercised.
Key Highlights
- Public offering closed on May 19, 2026, generating approximately $6 million in gross proceeds.
- Offering included 11,160,000 Common Units and 840,000 Pre-Funded Units.
- Common Units priced at $0.50; Pre-Funded Units at $0.49999.
- Each unit included two Series C Warrants, exercisable at $0.50 for five years.
- Pre-Funded Warrants are immediately exercisable at $0.00001.
- Placement agent Aegis Capital Corp. received a 7% fee and 2% expense allowance.
- Potential for an additional $12 million in gross proceeds from full warrant exercise.
- Net proceeds are designated for general corporate purposes and working capital.
Price Impact
More from SBFM